miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2

Circ Res. 2009 Feb 27;104(4):514-21. doi: 10.1161/CIRCRESAHA.108.181651. Epub 2009 Jan 8.

Abstract

MicroRNAs are small endogenous noncoding RNAs that regulate protein expression by hybridization to imprecise complementary sequences of target mRNAs. Changes in abundance of muscle-specific microRNA, miR-1, have been implicated in cardiac disease, including arrhythmia and heart failure. However, the specific molecular targets and cellular mechanisms involved in the action of miR-1 in the heart are only beginning to emerge. In this study we investigated the effects of increased expression of miR-1 on excitation-contraction coupling and Ca(2+) cycling in rat ventricular myocytes using methods of electrophysiology, Ca(2+) imaging and quantitative immunoblotting. Adenoviral-mediated overexpression of miR-1 in myocytes resulted in a marked increase in the amplitude of the inward Ca(2+) current, flattening of Ca(2+) transients voltage dependence, and enhanced frequency of spontaneous Ca(2+) sparks while reducing the sarcoplasmic reticulum Ca(2+) content as compared with control. In the presence of isoproterenol, rhythmically paced, miR-1-overexpressing myocytes exhibited spontaneous arrhythmogenic oscillations of intracellular Ca(2+), events that occurred rarely in control myocytes under the same conditions. The effects of miR-1 were completely reversed by the CaMKII inhibitor KN93. Although phosphorylation of phospholamban was not altered, miR-1 overexpression increased phosphorylation of the ryanodine receptor (RyR2) at S2814 (Ca(2+)/calmodulin-dependent protein kinase) but not at S2808 (protein kinase A). Overexpression of miR-1 was accompanied by a selective decrease in expression of the protein phosphatase PP2A regulatory subunit B56alpha involved in PP2A targeting to specialized subcellular domains. We conclude that miR-1 enhances cardiac excitation-contraction coupling by selectively increasing phosphorylation of the L-type and RyR2 channels via disrupting localization of PP2A activity to these channels.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Arrhythmias, Cardiac / enzymology*
  • Arrhythmias, Cardiac / genetics
  • Arrhythmias, Cardiac / physiopathology
  • Benzylamines / pharmacology
  • Calcium Channels, L-Type / metabolism
  • Calcium Signaling* / drug effects
  • Calcium Signaling* / genetics
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Cells, Cultured
  • Genetic Vectors
  • Isoproterenol / pharmacology
  • Membrane Potentials
  • Mice
  • MicroRNAs / metabolism*
  • Myocardial Contraction* / drug effects
  • Myocardial Contraction* / genetics
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / enzymology*
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Phosphatase 2 / metabolism*
  • Rats
  • Ryanodine Receptor Calcium Release Channel / metabolism*
  • Sarcoplasmic Reticulum / metabolism
  • Sulfonamides / pharmacology
  • Time Factors
  • Transduction, Genetic

Substances

  • Adrenergic beta-Agonists
  • Benzylamines
  • Calcium Channels, L-Type
  • MicroRNAs
  • Mirn1 microRNA, mouse
  • Protein Kinase Inhibitors
  • Ryanodine Receptor Calcium Release Channel
  • Sulfonamides
  • KN 93
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • B56alpha protein, rat
  • Protein Phosphatase 2
  • Isoproterenol